Skip to main content
SpringerLink
Log in

Kardio-metabolische Risikoreduktion

Welche Zielwerte sind bei Typ-2-Diabetes relevant?

Prevention of CV complications in DM2 — which targets should be used?

  • FORTBILDUNG . SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Typ-2-Diabetiker sind kardiovaskulär besonders gefährdet. Eine reine HbA1c-Fokussierung zur Risikoreduktion ist aber nicht mehr zeitgemäß. Die Therapie muss auch eine konsequente Blutdruck- und LDL-Cholesterin-Kontrolle erreichen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. ADA: American Diabetes Association Standards of Medical Care in Diabetes—2019; Diabetes Care 2019 Jan; 42(Supplement 1): S103-S123.

  2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 Oct;36(10):1953–2041.

    Article  CAS  Google Scholar 

  3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), European Heart Journal,, ehz455, https://doi.org/10.1093/eurheartj/ehz455

  4. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018 Dec;61(12):2461–2498

    Article  Google Scholar 

  5. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferoviæ PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019 Aug 31pii: ehz486. doi: 10.1093

  6. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bĕlohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Sep 19. doi: https://doi.org/10.1056/NEJMoa1911303. [Epub ahead of print]

  7. Eeg-Olofsson K, Zethelius B, Gudbjörnsdottir S, Eliasson B, Svensson AM, Cederholm J: Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register. Diab Vasc Dis Res. 2016 Jul;13(4):268–77

    Article  CAS  Google Scholar 

  8. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018 Aug 16;379(7):633–644.

    Article  Google Scholar 

  9. Eckel, RH, Blaha, MJ: cardiometabolic Medicine: A Call for a New Subspeciality Training Track in Internal Medicine, AM J Med, 2019: 7; 132, 788-790

    Google Scholar 

  10. Krentz AJ, Jacob S: Cardiometabolic medicine: time to recognize a new clinical specialty? Cardiovascular Endocrinology & Metabolism 2019, 8:47–48

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brombeerweg 6, D-78048, Villingen-Schwenningen, Deutschland

    Stephan Jacob (Internist, Endokrinologe, Diabetologe, Hypertensiologe, Ernährungsmediziner und Kardio-vaskulärer Präventionsmediziner DGPR, Praxis für Prävention und Therapie)

Authors
  1. Stephan Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Jacob.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jacob, S. Welche Zielwerte sind bei Typ-2-Diabetes relevant?. MMW - Fortschritte der Medizin 161, 37–41 (2019). https://doi.org/10.1007/s15006-019-1058-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-019-1058-7

Keywords

Search

Navigation